Seminar & Colloquium
[세미나: 7월 11일(화), 오전 11시] Prof. YOONJEE PARK,University of Cincinnati
TITLE
Dose-controllable Long-term Drug Delivery Implant
SPEAKER
Prof. YOONJEE PARK, Department of Chemical and Environmental Engineering, University of Cincinnati
EDUCATION
- 2010 - 2014 Postdoctoral training in Biomedical Engineering, Boston University, Boston, MA.
- 2006 - 2010 Ph. D. in Chemical Engineering, School of Chemical Engineering, Purdue University, West Lafayette, IN
- 2002 - 2006 Bachelor of Science in Chemical & Biological Engineering (with Honor), Seoul National University (SNU), Seoul, Korea
PROFESSIONAL EXPERIENCE
- 2022 - current Product Development Engineer, Jiangling LEAR Interior System Co. Ltd
- 2019 - 2022 Assistant Professor, Department of Chemical & Environmental Engineering, University of Cincinnati
- 2017 - 2022 Assistant Professor, Department of Chemical & Environmental Engineering, University of Cincinnati
- 2015 - 2022 Assistant Professor, Department of Biomedical, Chemical, & Environmental Engineering, University of Cincinnati
- 2013 - 2014 Postdoctoral Research Associate, Research Laboratory of Electronics, MIT, Cambridge, MA
- 2010 - 2013 Postdoctoral Research Associate, Department of Biomedical Engineering, Boston University, Boston, MA
- 2006 - 2010 Graduate Research Associate, School of Chemical Engineering, Purdue University, West Lafayette, IN
- 2005 - 2006 Undergraduate Research Assistant, Seoul National University, Seoul, Korea
| Date | Tuesday, July 11th, 2023
| Time | 11:00 ~
| Venue | 신소재공동연구소(131동) 1층 세미나실(제1세미나실)
[Abstract]
Repetitive intravitreal injections of drug or intravitreal injections of sustained-release corticosteroid implants (Ozurdex, Retisert, and Iluvien) are the current standard of care for the chronic diseases. However, these methods involve complications due to the high initial dose at the time of injection, known as burst release.
In this study, we have developed a size-exclusive nanoporous biodegradable polymer capsule for dosage-controllable drug delivery implants to avoid the burst release and control the dose only when needed. Light-activated liposomal drug (methotrexate) was enclosed in the polymer capsule. Methotrexate (MTX) was released through the capsule membrane when the implant was activated by laser, leaving the liposomal drug in the capsule. We have optimized the porosity and the pore size for MTX release kinetics, and tested the stability and the safety for 6 months in vivo rabbit eyes. We also demonstrated MTX release in vivo by irradiating near infrared laser (NIR, 1064 nm) through the lens of rabbit eyes. Lastly, we also demonstrated biodegradable sustained-release monoclonal antibody implant, which releases monoclonal antibodies slowly for 8 months to date. The technology allows us to avoid monthly invasive injections, which is the current standard of care for most chronic diseases that require antibodies as therapeutics. The drug delivery system that we developed is a platform technology which can be applied to different and/or multiple drugs. More importantly, the dose-controllability can avoid any side effects associated with high dose or uncontrollable dose.
| Host | 도준상 교수(02-880-1605)